Regeneron Delivers Strong Third Quarter But Sees Higher R&D

The Street
The Street
  • 4 years ago
Regeneron posts earnings that beat forecasts but cautions ongoing development of its Covid-19 vaccine candidate and other drugs mean higher R&D costs.

Recommended

0:35
I
Up next
[Read] Patents for Chemicals, Pharmaceuticals and Biotechnology For Kindle
Asher Battle
0:39
[Read] Patents for Chemicals, Pharmaceuticals and Biotechnology Best Sellers Rank : #2
dm_c323e93634b6d3108b10f21040648af2
9:59
THE RUNDOWN | Teva Pharmaceuticals reports jump in earnings | Thursday, May 3rd 2018
i24NEWS (English)
0:40
Popular Patents for Chemicals, Pharmaceuticals, and Biotechnology
kilivi
0:48
Regeneron Is the Stock to Watch on Booster Approval: Jim Cramer
The Street
3:30
Cramer: Regeneron's COVID-19 Drug Is the 'Missing Ingredient'
The Street
1:37
Covid-19 : ces essais très prometteurs du traitement de Regeneron
Le Point Abonnés
1:37
Covid-19 : ces essais très prometteurs du traitement de Regeneron
Le Point Actu
2:14
Jim Cramer Identifies Regeneron's Biggest Challenge Ahead
The Street
1:24
Covid : Les Etats-Unis autorisent le Regeneron
CNEWS

The Street

1:39
Walmart stock hits all-time high
The Street
3:04
How content creation on YouTube has evolved
The Street
1:53
Grocery prices finally start to come down
The Street
2:00
Uber unveils Uber Shuttle at 2024 Go-Get event
The Street
2:39
Beyonce's net worth: How the pop icon built a $800 million fortune
The Street
2:18
How to deal with social media envy
The Street

Featured channels

More from
SportsGrid
More from
TMZ
More from
Genius
More from
Eater
More from
AccuWeather
More from
Delish